Close

Moderna (MRNA) R&D Day Highlights COVID-19 Vaccine - Goldman Sachs

September 21, 2020 6:16 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $107.00 price target on Moderna (NASDAQ: MRNA) after attending the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login